ATP10D

Summary

ATP10D (ATPase phospholipid transporting 10D (putative), HGNC:13549) is a protein-coding gene on chromosome 4p12, encoding Phospholipid-transporting ATPase VD (Q9P241). Catalytic component of a P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of glucosylceramide (GlcCer) from the outer to the inner leaflet of the plasma membrane.

Enables glycosylceramide flippase activity. Predicted to be involved in phospholipid translocation. Located in endoplasmic reticulum; nucleoplasm; and plasma membrane. Part of phospholipid-translocating ATPase complex.

Source: NCBI Gene 57205 — RefSeq curated summary.

At a glance

• GWAS associations: 19
• Clinical variants (ClinVar): 201 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_020453

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13549
Approved symbol	ATP10D
Name	ATPase phospholipid transporting 10D (putative)
Location	4p12
Locus type	gene with protein product
Status	Approved
Aliases	ATPVD, KIAA1487
Ensembl gene	ENSG00000145246
Ensembl biotype	protein_coding
OMIM	619815
Entrez	57205

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 8 protein_coding, 3 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000273859, ENST00000503288, ENST00000504445, ENST00000505277, ENST00000505476, ENST00000507889, ENST00000512393, ENST00000907879, ENST00000907880, ENST00000907881, ENST00000917244, ENST00000917246, ENST00000951777

RefSeq mRNA: 1 — MANE Select: NM_020453 NM_020453

CCDS: CCDS3476

Canonical transcript exons

ENST00000273859 — 23 exons

Exon	Start	End
ENSE00001122033	47535902	47536033
ENSE00001122038	47535509	47535615
ENSE00001122042	47525557	47525642
ENSE00001210501	47546624	47546862
ENSE00001210504	47536686	47536938
ENSE00001210508	47536437	47536564
ENSE00001210512	47591042	47593486
ENSE00001210524	47523012	47523216
ENSE00001210533	47515476	47515670
ENSE00001210542	47512504	47512830
ENSE00001295580	47554726	47554914
ENSE00001319074	47557664	47558273
ENSE00001927498	47485275	47485519
ENSE00003508466	47580398	47580478
ENSE00003527843	47558923	47559029
ENSE00003552319	47581960	47582064
ENSE00003563070	47572154	47572230
ENSE00003578397	47587019	47587206
ENSE00003587764	47563581	47563765
ENSE00003638268	47568837	47569146
ENSE00003660954	47576773	47576973
ENSE00003666093	47572872	47572997
ENSE00003692134	47560949	47561075

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 95.33.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.3892 / max 302.3318, expressed in 1593 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
47553	12.5398	1589
47554	0.4584	245
47552	0.3910	202

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	95.33	gold quality
secondary oocyte	CL:0000655	94.00	gold quality
placenta	UBERON:0001987	93.94	gold quality
adrenal tissue	UBERON:0018303	93.68	gold quality
upper leg skin	UBERON:0004262	93.35	gold quality
oocyte	CL:0000023	93.13	gold quality
choroid plexus epithelium	UBERON:0003911	93.01	gold quality
gingival epithelium	UBERON:0001949	92.77	gold quality
calcaneal tendon	UBERON:0003701	92.77	gold quality
gingiva	UBERON:0001828	92.38	gold quality
skin of hip	UBERON:0001554	92.30	gold quality
descending thoracic aorta	UBERON:0002345	92.24	gold quality
hair follicle	UBERON:0002073	91.87	gold quality
thoracic aorta	UBERON:0001515	91.76	gold quality
ascending aorta	UBERON:0001496	91.71	gold quality
tibia	UBERON:0000979	90.83	gold quality
tongue squamous epithelium	UBERON:0006919	90.55	gold quality
metanephric glomerulus	UBERON:0004736	90.42	gold quality
renal glomerulus	UBERON:0000074	90.40	gold quality
penis	UBERON:0000989	90.35	gold quality
metanephros	UBERON:0000081	90.14	gold quality
aorta	UBERON:0000947	89.73	gold quality
cauda epididymis	UBERON:0004360	89.62	gold quality
blood vessel layer	UBERON:0004797	89.54	gold quality
caput epididymis	UBERON:0004358	89.53	gold quality
urethra	UBERON:0000057	89.30	gold quality
right coronary artery	UBERON:0001625	89.28	gold quality
squamous epithelium	UBERON:0006914	89.14	gold quality
oral cavity	UBERON:0000167	89.08	gold quality
esophagus squamous epithelium	UBERON:0006920	89.02	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9221	yes	1981.04
E-ANND-3	yes	6.15
E-MTAB-9801	yes	5.53

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

95 targeting ATP10D, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-182-5P	99.87	74.03	2589
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-659-3P	99.85	70.69	1620
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-2052	99.79	69.37	2031

Literature-anchored findings (GeneRIF, showing 1)

• The rs2351791 SNP in the Atp10d gene affects the susceptibility for cardiac and intracranial vascular stenosis in the elderly Japanese population. (PMID:24125428)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	atp10d	ENSDARG00000078887
mus_musculus	Atp10d	ENSMUSG00000046808
rattus_norvegicus	Atp10d	ENSRNOG00000002312
drosophila_melanogaster	CG9981	FBGN0030746
drosophila_melanogaster	CG4301	FBGN0030747
drosophila_melanogaster	CG31729	FBGN0051729
caenorhabditis_elegans	tat-5	WBGENE00009498
caenorhabditis_elegans		WBGENE00017174

Paralogs (13): ATP9A (ENSG00000054793), ATP11B (ENSG00000058063), ATP11A (ENSG00000068650), ATP8B1 (ENSG00000081923), ATP11C (ENSG00000101974), ATP8B4 (ENSG00000104043), ATP10B (ENSG00000118322), ATP8A1 (ENSG00000124406), ATP8B3 (ENSG00000130270), ATP8A2 (ENSG00000132932), ATP8B2 (ENSG00000143515), ATP9B (ENSG00000166377), ATP10A (ENSG00000206190)

Protein

Protein identifiers

Phospholipid-transporting ATPase VD — Q9P241 (reviewed: Q9P241)

Alternative names: ATPase class V type 10D, P4-ATPase flippase complex alpha subunit ATP10D

All UniProt accessions (3): Q9P241, H0Y8M7, Q6PEW3

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic component of a P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of glucosylceramide (GlcCer) from the outer to the inner leaflet of the plasma membrane.

Subunit / interactions. Component of a P4-ATPase flippase complex which consists of a catalytic alpha subunit ATP10A and an accessory beta subunit TMEM30A.

Subcellular location. Cell membrane. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in placenta and, to a lesser extent, in kidney.

Post-translational modifications. Autophosphorylated at the conserved aspartate of the P-type ATPase signature sequence.

Similarity. Belongs to the cation transport ATPase (P-type) (TC 3.A.3) family. Type IV subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9P241-1	1	yes
Q9P241-2	2

RefSeq proteins (1): NP_065186* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001757	P_typ_ATPase	Family
IPR006539	P-type_ATPase_IV	Family
IPR008250	ATPase_P-typ_transduc_dom_A_sf	Homologous_superfamily
IPR018303	ATPase_P-typ_P_site	PTM
IPR023214	HAD_sf	Homologous_superfamily
IPR023298	ATPase_P-typ_TM_dom_sf	Homologous_superfamily
IPR023299	ATPase_P-typ_cyto_dom_N	Homologous_superfamily
IPR032630	P_typ_ATPase_c	Domain
IPR032631	P-type_ATPase_N	Domain
IPR036412	HAD-like_sf	Homologous_superfamily
IPR044492	P_typ_ATPase_HD_dom	Domain

Pfam: PF13246, PF16209, PF16212

Enzyme classification (BRENDA):

• EC 7.6.2.1 — P-type phospholipid transporter (BRENDA: 22 organisms, 260 substrates, 62 inhibitors, 53 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.016–2.215	41
P-NITROPHENYL PHOSPHATE	1.17–1.46	3
ACETYL PHOSPHATE	1.03–1.31	2
1-PALMITOYL-2-OLEOYL-SN-GLYCERO-3-PHOSPHO-L-SERI	0.111	1

Catalyzed reactions (Rhea), 1 shown:

• a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine(out) + ATP + H2O = a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine(in) + ADP + phosphate + H(+) (RHEA:66036)

UniProt features (67 total): binding site 20, sequence variant 13, topological domain 11, transmembrane region 10, mutagenesis site 5, sequence conflict 3, chain 1, region of interest 1, compositionally biased region 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P241-F1	72.97	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 438 (4-aspartylphosphate intermediate)

Ligand- & substrate-binding residues (20): 438; 438; 439; 440; 440; 730; 772; 796; 840; 920; 921; 922 …

Mutagenesis-validated functional residues (5):

Position	Phenotype
110–111	impairs atpase flippase activity.
215	impairs atpase flippase activity.
381	impairs atpase flippase activity.
382	increases atpase flippase activity.
1148–1149	impairs atpase flippase activity.

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-382551	Transport of small molecules
R-HSA-983712	Ion channel transport

MSigDB gene sets: 240 (showing top): DITTMER_PTHLH_TARGETS_UP, CREBP1_Q2, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, GOBP_MONOATOMIC_CATION_TRANSPORT, chr4p12, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, LI_WILMS_TUMOR_VS_FETAL_KIDNEY_1_UP, HUTTMANN_B_CLL_POOR_SURVIVAL_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, E4F1_Q6, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, DOUGLAS_BMI1_TARGETS_DN, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, GOBP_PHOSPHOLIPID_TRANSPORT, GOBP_MEMBRANE_ORGANIZATION

GO Biological Process (6): monoatomic cation transport (GO:0006812), monoatomic ion transmembrane transport (GO:0034220), phospholipid translocation (GO:0045332), lipid transport (GO:0006869), phospholipid transport (GO:0015914), lipid translocation (GO:0034204)

GO Molecular Function (9): magnesium ion binding (GO:0000287), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), ATPase-coupled intramembrane lipid carrier activity (GO:0140326), glycosylceramide flippase activity (GO:0140351), nucleotide binding (GO:0000166), transporter activity (GO:0005215), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (6): nucleoplasm (GO:0005654), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020), phospholipid-translocating ATPase complex (GO:1990531)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Ion channel transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monoatomic ion transport	2
lipid transport	2
ATP-dependent activity	2
cellular anatomical structure	2
transmembrane transport	1
phospholipid transport	1
lipid translocation	1
transport	1
lipid localization	1
organophosphate ester transport	1
regulation of membrane lipid distribution	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
intramembrane lipid carrier activity	1
sphingolipid intramembrane carrier activity	1
flippase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
molecular_function	1
binding	1
cation binding	1
nuclear lumen	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
membrane	1
cell periphery	1
transporter complex	1

Protein interactions and networks

STRING

1026 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP10D	CDC50A	Q9NV96	639
ATP10D	CDC50B	Q3MIR4	551
ATP10D	TMEM86B	Q8N661	541
ATP10D	NCEH1	Q6PIU2	524
ATP10D	TRIML1	Q8N9V2	514
ATP10D	BEND5	Q7L4P6	507
ATP10D	MS4A5	Q9H3V2	428
ATP10D	GCAT	O75600	427
ATP10D	ATP10A	O60312	419
ATP10D	ADGRF5	Q8IZF2	418
ATP10D	DPEP2	Q9H4A9	418
ATP10D	PROX1	Q92786	409
ATP10D	ATP10B	O94823	405
ATP10D	TMEM268	Q5VZI3	401
ATP10D	VSNL1	P28677	397

IntAct

3 interactions, top by confidence:

A	B	Type	Score
ATP10D	TMEM30A	psi-mi:“MI:0915”(physical association)	0.400
ATP10D	VMA21	psi-mi:“MI:0914”(association)	0.350

BioGRID (9): ATP10D (Affinity Capture-RNA), ATP10D (Proximity Label-MS), ATP10D (Affinity Capture-RNA), ATP10D (Affinity Capture-MS), EPDR1 (Affinity Capture-MS), VMA21 (Affinity Capture-MS), ATP10D (Affinity Capture-MS), ATP10D (Proximity Label-MS), ATP10D (Affinity Capture-RNA)

ESM2 similar proteins: A0A131MCZ8, A3KMI0, A6H8T7, A7T1N0, B1AWN4, B7ZC32, D3ZEY4, D3ZSI8, F4INY4, G0S196, O36028, O54827, O60312, O60353, O60423, O62852, O94823, P21441, P22717, P32660, P34586, P49619, P49620, Q01063, Q03603, Q09891, Q12675, Q2NKY8, Q38SD2, Q39017, Q3UHC2, Q5BJS0, Q5CZZ9, Q5R607, Q5ZI74, Q6P158, Q6P5D3, Q6P5E8, Q6UQ17, Q7L2E3

Diamond homologs: A1A4J6, A3FIN4, B1AWN4, C7EXK4, D4AA47, D4ABB8, F1Q4S1, G0S196, G2X7W6, G5EBH1, O36028, O43520, O43861, O54827, O60312, O60423, O94296, O94823, P32660, P39524, P40527, P57792, P70704, P98195, P98196, P98197, P98198, P98199, P98200, P98204, P98205, Q09891, Q10309, Q12675, Q148W0, Q29449, Q37145, Q5BL50, Q6DFW5, Q6UQ17

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

201 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	164
Likely benign	12
Benign	1

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
58027	GRCh38/hg38 4p13-11(chr4:44577678-49081273)x3	Pathogenic
694454	GRCh37/hg19 4p12-11(chr4:45868775-48273513)x3	Likely pathogenic

SpliceAI

4759 predictions. Top by Δscore:

Variant	Effect	Δscore
4:47493857:T:A	acceptor_gain	1.0000
4:47523004:A:AG	acceptor_gain	1.0000
4:47523005:A:G	acceptor_gain	1.0000
4:47523008:ACAG:A	acceptor_gain	1.0000
4:47523009:C:G	acceptor_gain	1.0000
4:47523009:CAGG:C	acceptor_loss	1.0000
4:47523010:A:AG	acceptor_gain	1.0000
4:47523010:AG:A	acceptor_gain	1.0000
4:47523011:G:GT	acceptor_gain	1.0000
4:47523011:GG:G	acceptor_gain	1.0000
4:47523011:GGA:G	acceptor_gain	1.0000
4:47523011:GGAA:G	acceptor_gain	1.0000
4:47523011:GGAAA:G	acceptor_gain	1.0000
4:47523214:CAGGT:C	donor_loss	1.0000
4:47523215:AGG:A	donor_loss	1.0000
4:47523217:G:GG	donor_gain	1.0000
4:47523217:GT:G	donor_loss	1.0000
4:47523218:T:A	donor_loss	1.0000
4:47525641:CTG:C	donor_loss	1.0000
4:47525642:TG:T	donor_loss	1.0000
4:47525643:G:GC	donor_loss	1.0000
4:47525643:G:GG	donor_gain	1.0000
4:47525644:T:A	donor_loss	1.0000
4:47525646:AG:A	donor_loss	1.0000
4:47525647:G:C	donor_loss	1.0000
4:47536709:T:G	acceptor_gain	1.0000
4:47536716:A:AG	acceptor_gain	1.0000
4:47536716:ATC:A	acceptor_gain	1.0000
4:47536717:T:G	acceptor_gain	1.0000
4:47536718:C:CA	acceptor_gain	1.0000

AlphaMissense

9372 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:47536891:T:C	F450S	0.999
4:47558018:A:C	S727R	0.999
4:47558020:C:A	S727R	0.999
4:47558020:C:G	S727R	0.999
4:47572169:A:C	D1060A	0.999
4:47512698:T:A	V53D	0.998
4:47535607:T:A	V292D	0.998
4:47536855:A:C	D438A	0.998
4:47569090:A:T	K1036I	0.998
4:47572168:G:C	D1060H	0.998
4:47572169:A:T	D1060V	0.998
4:47523040:T:A	W172R	0.997
4:47523040:T:C	W172R	0.997
4:47523139:T:C	C205R	0.997
4:47525599:T:C	C245R	0.997
4:47535562:G:C	R277T	0.997
4:47535597:G:C	G289R	0.997
4:47535911:C:T	T298I	0.997
4:47536855:A:T	D438V	0.997
4:47536885:T:C	M448T	0.997
4:47536890:T:C	F450L	0.997
4:47536892:T:A	F450L	0.997
4:47536892:T:G	F450L	0.997
4:47536899:T:C	C453R	0.997
4:47558046:C:A	A736D	0.997
4:47558049:C:A	A737D	0.997
4:47558153:T:C	F772L	0.997
4:47558155:T:A	F772L	0.997
4:47558155:T:G	F772L	0.997
4:47558177:T:C	S780P	0.997

dbSNP variants (sampled 300 via entrez): RS1000035718 (4:47519704 C>A,G,T), RS10000432 (4:47509764 T>A,C,G), RS1000047450 (4:47518592 A>C), RS1000096519 (4:47562534 G>T), RS10001204 (4:47537187 G>A), RS1000135805 (4:47566226 A>G), RS1000187872 (4:47570649 C>G,T), RS1000187902 (4:47483928 T>C), RS1000233402 (4:47494590 C>T), RS1000233645 (4:47555758 CTT>C,CT,CTTT,CTTTT,CTTTTT,CTTTTTTT), RS1000246200 (4:47559757 C>T), RS1000250701 (4:47566629 T>C), RS10002592 (4:47576174 A>C,G,T), RS10002787 (4:47495794 A>C,G,T), RS1000303556 (4:47581405 G>T)

Disease associations

OMIM: gene MIM:619815 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST000493_1	Sphingolipid levels	8.000000e-19
GCST001413_10	Sphingolipid levels	2.000000e-19
GCST009255_4	Fourth ventricle volume	6.000000e-06
GCST009698_33	Metabolite levels	5.000000e-06
GCST009698_81	Metabolite levels	3.000000e-15
GCST009698_83	Metabolite levels	6.000000e-10
GCST009698_85	Metabolite levels	4.000000e-13
GCST009698_86	Metabolite levels	6.000000e-16
GCST009698_88	Metabolite levels	2.000000e-16
GCST009698_89	Metabolite levels	2.000000e-17
GCST009698_92	Metabolite levels	9.000000e-15
GCST009698_93	Metabolite levels	5.000000e-15
GCST009698_94	Metabolite levels	3.000000e-08
GCST009698_96	Metabolite levels	2.000000e-08
GCST009698_97	Metabolite levels	4.000000e-08
GCST012020_1	Serum metabolite levels	8.000000e-40
GCST012020_100	Serum metabolite levels	3.000000e-24
GCST012020_276	Serum metabolite levels	1.000000e-25
GCST012020_277	Serum metabolite levels	1.000000e-15

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — P4 P-type ATPases: Phospholipid-transporting ATPases

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	8
Cyclosporine	decreases expression, increases expression	3
sodium arsenite	decreases expression, increases abundance, affects cotreatment	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression, increases expression	2
Acetaminophen	increases expression	2
Arsenic	affects cotreatment, decreases expression, increases abundance	2
Benzo(a)pyrene	affects methylation, increases mutagenesis	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
GSK-J4	decreases expression	1
FR900359	increases phosphorylation	1
sotorasib	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
phenethyl isothiocyanate	increases expression	1
chromium hexavalent ion	decreases expression	1
2-palmitoylglycerol	increases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	increases expression, affects cotreatment	1
Vorinostat	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Cadmium	increases abundance, increases expression	1
Cytarabine	increases expression	1
Doxorubicin	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms